Drug class definitions for Elotuzumab

Elotuzumab(Elotuzumab) is a monoclonal antibody that is an immunostimulatory antibody against SLAMF7 (Signaling Lymphocytic Activation Molecule Family Member 7). SLAMF7 is a protein highly expressed on the surface of multiple myeloma (MM) cells and natural killer (NK) cells. It plays a key role in immune regulation and tumor microenvironment. By targeting SLAMF7, evolizumab can directly activate NK cell-mediated anti-tumor effects and at the same time enhance the clearance of myeloma cells through antibody-dependent cellular cytotoxicity (ADCC).

As an immune-stimulating antibody, evolizumab's therapeutic strategy not only relies on direct tumor killing, but also emphasizes regulating the activity of the patient's own immune system. This mechanism of action gives it a unique therapeutic advantage in adult patients with multiple myeloma, especially in combination with immunomodulators, which can significantly enhance NK cell activity and anti-tumor response. Overseas guidelines and clinical studies have shown that evolizumab can achieve more durable disease control by synergizing with immunomodulators through SLAMF7 targeting, and at the same time exhibits a controllable toxicity spectrum in long-term treatment.

Unlike traditional chemotherapy drugs, evolizumab's targeted immune mechanism makes it an important option for patients with drug-resistant or relapsed multiple myeloma. Its drug types are positioned in the precision immunotherapy category, emphasizing intervention in tumors by activating the body's immune system rather than relying solely on cytotoxic killing. With the deepening of clinical practice, evolizumab has gradually been included in the preferred combination regimen in the standard treatment regimen for multiple myeloma, especially for patients who have failed previous treatments or are at high risk of recurrence.

In general, evolizumab is an immunostimulatory antibody againstSLAMF7. Its drug type and mechanism of action determine its core value in the treatment of adult patients with multiple myeloma. By activating NK cells and ADCC pathways, the drug not only provides direct anti-tumor effects, but also synergizes with immune modulators to provide patients with scientific, precise and sustainable treatment options.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80686b7e-f6f4-4154-b5c0-c846425e2d91